482 related articles for article (PubMed ID: 21838140)
1. [Clinical significance of cytochrome P450 genetic polymorphism--part I. Enzymatic system of cytochrome P450 and cytochrome P450 1A2].
Duricová J; Grundmann M
Ceska Slov Farm; 2011 Jun; 60(3):110-5. PubMed ID: 21838140
[TBL] [Abstract][Full Text] [Related]
2. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
Lynch T; Price A
Am Fam Physician; 2007 Aug; 76(3):391-6. PubMed ID: 17708140
[TBL] [Abstract][Full Text] [Related]
3. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.
Zhou SF; Wang B; Yang LP; Liu JP
Drug Metab Rev; 2010 May; 42(2):268-354. PubMed ID: 19961320
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.
Ingelman-Sundberg M
Trends Pharmacol Sci; 2004 Apr; 25(4):193-200. PubMed ID: 15063083
[TBL] [Abstract][Full Text] [Related]
5. [Advance in cytochrome P450 1A2].
Xiao P; Zhou HH
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 May; 33(5):456-60. PubMed ID: 18544853
[TBL] [Abstract][Full Text] [Related]
6. Bench to bedside: Pharmacogenomics, adverse drug interactions, and the cytochrome P450 system.
Sikka R; Magauran B; Ulrich A; Shannon M
Acad Emerg Med; 2005 Dec; 12(12):1227-35. PubMed ID: 16282513
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
Zhou SF; Liu JP; Chowbay B
Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphism and toxicology--with emphasis on cytochrome p450.
Johansson I; Ingelman-Sundberg M
Toxicol Sci; 2011 Mar; 120(1):1-13. PubMed ID: 21149643
[TBL] [Abstract][Full Text] [Related]
9. Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS; Kim D
Arch Pharm Res; 2011 Nov; 34(11):1799-816. PubMed ID: 22139682
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. III. Influence of CYP genetic polymorphism on population differentiation of drug metabolism phenotype.
Tomaszewski P; Kubiak-Tomaszewska G; Łukaszkiewicz J; Pachecka J
Acta Pol Pharm; 2008; 65(3):319-29. PubMed ID: 18646551
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome p450 part 2: what nurses need to know about the cytochrome p450 family systems.
Krau SD
Nurs Clin North Am; 2013 Dec; 48(4):681-96. PubMed ID: 24295195
[TBL] [Abstract][Full Text] [Related]
12. Is genetic testing for cytochrome P450 polymorphisms ready for implementation?
Matchar DB; Thakur M
Am Fam Physician; 2007 Aug; 76(3):348, 351. PubMed ID: 17708133
[No Abstract] [Full Text] [Related]
13. Cytochromes P450: decision-making tools for personalized therapeutics.
Murray M; Petrovic N
Curr Opin Mol Ther; 2006 Dec; 8(6):480-6. PubMed ID: 17243482
[TBL] [Abstract][Full Text] [Related]
14. Development of a high throughput single nucleotide polymorphism screening method for the cytochrome P450 1A2 polymorphisms CYP1A2*1C and CYP1A2*1F: are they useful as predictive markers in mental disorders?
Klemm M; Eidens M; Lorenz M; Prause S; Weise A; Dahmen N; Forst T; Pfützner A
Clin Lab; 2010; 56(9-10):473-80. PubMed ID: 21086794
[TBL] [Abstract][Full Text] [Related]
15. Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction?
Tang C; Lin JH; Lu AY
Drug Metab Dispos; 2005 May; 33(5):603-13. PubMed ID: 15673596
[TBL] [Abstract][Full Text] [Related]
16. Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: some answers but still questions.
Wilkinson GR
Clin Pharmacol Ther; 2004 Aug; 76(2):99-103. PubMed ID: 15289786
[No Abstract] [Full Text] [Related]
17. [Pharmacogenetics and its importance in the clinical].
Lares-Asseff I; Trujillo-Jiménez F
Gac Med Mex; 2001; 137(3):227-36. PubMed ID: 11432091
[TBL] [Abstract][Full Text] [Related]
18. Interaction between cytochrome P450 1A2 genetic polymorphism and cigarette smoking on the risk of hepatocellular carcinoma in a Japanese population.
Imaizumi T; Higaki Y; Hara M; Sakamoto T; Horita M; Mizuta T; Eguchi Y; Yasutake T; Ozaki I; Yamamoto K; Onohara S; Kawazoe S; Shigematsu H; Koizumi S; Kudo S; Tanaka K
Carcinogenesis; 2009 Oct; 30(10):1729-34. PubMed ID: 19643819
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers.
Ma JD; Nafziger AN; Bertino JS
J Clin Pharmacol; 2004 May; 44(5):447-56. PubMed ID: 15102864
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics: has it reached the clinic?
Schwartz JB
J Gend Specif Med; 2002; 5(2):13-8. PubMed ID: 11974670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
